Bio-Hep-B vaccine

 

Prof. Yosef Shaul studies the processes by which viruses interact with cells. In particular, he has been able to define the molecular mechanisms employed by the hepatitis B virus.

 

 

Bio-Hep-B, a vaccine for hepatitis B based on Prof. Shaul's research, is produced by Biotechnology General and marketed in Israel; registrations in other countries are under way. Hepatitis B affects an estimated 150 million people in Africa and Asia.